keyword
MENU ▼
Read by QxMD icon Read
search

fluticasone

keyword
https://www.readbyqxmd.com/read/28102056/asthma-related-outcomes-in-patients-initiating-extrafine-ciclesonide-or-fine-particle-inhaled-corticosteroids
#1
Dirkje S Postma, Richard Dekhuijzen, Thys van der Molen, Richard J Martin, Wim van Aalderen, Nicolas Roche, Theresa W Guilbert, Elliot Israel, Daniela van Eickels, Javaria Mona Khalid, Ron M C Herings, Jetty A Overbeek, Cristiana Miglio, Victoria Thomas, Catherine Hutton, Elizabeth V Hillyer, David B Price
PURPOSE: Extrafine-particle inhaled corticosteroids (ICS) have greater small airway deposition than standard fine-particle ICS. We sought to compare asthma-related outcomes after patients initiated extrafine-particle ciclesonide or fine-particle ICS (fluticasone propionate or non-extrafine beclomethasone). METHODS: This historical, matched cohort study included patients aged 12-60 years prescribed their first ICS as ciclesonide or fine-particle ICS. The 2 cohorts were matched 1:1 for key demographic and clinical characteristics over the baseline year...
March 2017: Allergy, Asthma & Immunology Research
https://www.readbyqxmd.com/read/28057707/an-update-on-lama-laba-combinations-for-copd
#2
(no author information available yet)
The management of symptoms of chronic obstructive pulmonary disease (COPD) typically involves the use of inhaled long-acting bronchodilators. Previously, we have reviewed the long-acting muscarinic antagonists (LAMAs) ▼aclidinium,(1) ▼glycopyrronium,(2) tiotropium(3) and ▼umeclidinium,(4) and the long-acting beta2 agonists (LABAs) indacaterol,(5) ▼olodaterol,(6) and ▼vilanterol (in combination with fluticasone) in the management of COPD.(7) Four fixed-dose combinations of a LAMA with a LABA are now available, all indicated as maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD...
January 5, 2017: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/28056550/co-inhalation-of-roflumilast-rather-than-formoterol-with-fluticasone-more-effectively-improves-asthma-in-asthmatic-mice
#3
Hussam A Murad, Hamed S Habib, Misbahuddin M Rafeeq, Mansour I Sulaiman, Amer S Abdulrahman, Mohamad Nidal Khabaz
Roflumilast is approved as an add-on therapy for chronic obstructive pulmonary disease. The inflammation in chronic obstructive pulmonary disease is mainly neutrophilic, while in asthma it is mainly eosinophilic, studies addressing role of roflumilast in eosinophilic inflammation are recommended. Also in severe asthma, the dominant inflammatory cells are neutrophils. Thus, roflumilast has a potential off-label use in the treatment of asthma. This study was designed to evaluate the effects of co-inhalation of roflumilast and fluticasone compared to that of formoterol and fluticasone in ovalbumin-sensitized and-challenged BALB/c mice...
January 1, 2017: Experimental Biology and Medicine
https://www.readbyqxmd.com/read/28049170/airway-inflammation-in-copd-after-long-term-withdrawal-of-inhaled-corticosteroids
#4
Lisette I Z Kunz, Nick H T Ten Hacken, Thérèse S Lapperre, Wim Timens, Huib A M Kerstjens, Annemarie van Schadewijk, Judith M Vonk, Jacob K Sont, Jiska B Snoeck-Stroband, Dirkje S Postma, Peter J Sterk, Pieter S Hiemstra
Long-term treatment with inhaled corticosteroids (ICS) might attenuate lung function decline and decrease airway inflammation in a subset of patients with chronic obstructive pulmonary disease (COPD), and discontinuing ICS treatment could result in further lung function decline. We hypothesised that airway inflammation increases after ICS withdrawal following long-term ICS treatment in COPD.In the GLUCOLD-1 study (GL1), 114 patients with moderate-severe COPD were randomised to 6-month or 30-month treatment with fluticasone propionate (500 µg twice daily), 30-month treatment with fluticasone/salmeterol (500/50 µg twice daily) or placebo...
January 2017: European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology
https://www.readbyqxmd.com/read/28029916/effectiveness-of-fluticasone-furoate-vilanterol-in-copd
#5
LETTER
Samy Suissa
No abstract text is available yet for this article.
29, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/28029915/effectiveness-of-fluticasone-furoate-vilanterol-in-copd
#6
LETTER
Jørgen Vestbo
No abstract text is available yet for this article.
29, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/28008244/indacaterol-glycopyrronium-in-symptomatic-patients-with-copd-gold-b-and-gold-d-versus-salmeterol-fluticasone-illuminate-lantern-pooled-analysis
#7
Claus Vogelmeier, Nanshan Zhong, Michael J Humphries, Karen Mezzi, Robert Fogel, Giovanni Bader, Francesco Patalano, Donald Banerji
BACKGROUND: Indacaterol/glycopyrronium (IND/GLY) is approved for maintenance treatment of adult patients with COPD. This post hoc analysis explored the efficacy and safety of IND/GLY versus salmeterol/fluticasone (SFC) in symptomatic (Global Initiative for Chronic Obstructive Lung Disease [GOLD] B and GOLD D) patients with moderate-to-severe COPD. PATIENTS AND METHODS: Data from LANTERN and ILLUMINATE studies were pooled and analyzed. In both studies, symptomatic COPD patients were randomized to once-daily IND/GLY 110 μg/50 μg or twice-daily SFC 50 μg/500 μg...
2016: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/28008243/efficacy-of-tiotropium-olodaterol-fixed-dose-combination-in-copd
#8
REVIEW
Eric Derom, Guy G Brusselle, Guy F Joos
Tiotropium-olodaterol, formulated in the Respimat soft-mist inhaler, is an inhaled fixed-dose combination (FDC) of a long-acting muscarinic antagonist (LAMA) and a long-acting β2-agonist (LABA), commercialized under the name of Spiolto or Stiolto. The efficacy of tiotropium-olodaterol 5-5 μg once daily in adult patients with COPD was documented in eleven large, multicenter trials of up to 52 weeks duration. Tiotropium-olodaterol 5-5 μg not only improved spirometric values to a significantly greater extent than placebo but also resulted in statistically significant beneficial effects on dyspnea, markers of hyperinflation, use of rescue medication, health-related quality of life, and exercise endurance...
2016: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/28008228/spotlight-on-fluticasone-furoate-vilanterol-trifenatate-for-the-once-daily-treatment-of-asthma-design-development-and-place-in-therapy
#9
REVIEW
Timothy E Albertson, Samuel W Bullick, Michael Schivo, Mark E Sutter
The use of inhaled corticosteroids (ICSs) plays a key role in the treatment of asthmatic patients, and international guidelines have designated ICSs as an early maintenance therapy in controlling asthma symptoms. When asthmatic patients remain symptomatic on ICSs, one common option is to add a long-acting beta2 agonist (LABA) to the maintenance treatment. Fixed combination inhalers that contain both an ICS and a LABA have been popular for both chronic obstructive pulmonary disease (COPD) and asthma. Historically, these inhalers have been dosed twice daily...
2016: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28000962/hypoxia-causes-il-8-secretion-charcot-leyden-crystal-formation-and-suppression-of-corticosteroid-induced-apoptosis-in-human-eosinophils
#10
Linsey M Porter, Andrew S Cowburn, Neda Farahi, John Deighton, Stuart N Farrow, Christine A Fiddler, Jatinder K Juss, Alison M Condliffe, Edwin R Chilvers
BACKGROUND: Inflamed environments are typically hypercellular, rich in pro-inflammatory cytokines, and profoundly hypoxic. While the effects of hypoxia on neutrophil longevity and function have been widely studied, little is known about the consequences of this stimulus on eosinophils. OBJECTIVE: We sought to investigate the effects of hypoxia on several key aspects of eosinophil biology; namely secretion, survival, and their sensitivity to glucocorticosteroids (GCS), agents which normally induce eosinophil apoptosis...
December 21, 2016: Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/27987390/simultaneous-analysis-of-glucocorticosteroid-fluticasone-propionate-and-its-metabolite-fluticasone-propionate-17%C3%AE-carboxylic-acid-in-human-plasma-by-uplc-ms-ms-at-sub-pg-ml-level
#11
Sneha G Nair, Daxesh P Patel, Mallika Sanyal, Puran Singhal, Pranav S Shrivastav
A highly sensitive and rapid ultra performance liquid chromatography-tandem mass spectrometry method has been developed for the simultaneous determination of fluticasone propionate (FP) and its major metabolite, fluticasone propionate-17beta-carboxylic acid (FP 17β-CA) in human plasma. The analytes and their deuterated internal standards, FP-d3 and FP 17β-CA-d3 were extracted from 500μL plasma samples by solid phase extraction on Oasis MAX cartridges. The chromatographic analysis was performed on ACQUITY UPLC BEH C18 (50mm×2...
December 8, 2016: Journal of Pharmaceutical and Biomedical Analysis
https://www.readbyqxmd.com/read/27979015/inhaled-corticosteroids-effects-on-growth-and-bone-health
#12
David P Skoner
BACKGROUND: Both slowed growth in children and reduced bone mineral density (BMD) are systemic effects of corticosteroids, and there is concern about the degree to which these systemic effects affect growth and BMD. OBJECTIVE: To engage in a data-driven discussion of the effects of inhaled corticosteroids (ICSs) on growth in children and BMD. METHODS: Articles were selected based on their relevance to this review. RESULTS: Studies of ICSs in children in which growth was a secondary outcome have revealed slowed growth associated with low doses of budesonide, fluticasone propionate, and beclomethasone dipropionate...
December 2016: Annals of Allergy, Asthma & Immunology
https://www.readbyqxmd.com/read/27977309/drug-delivery-in-asthmatic-children-following-coordinated-and-uncoordinated-inhalation-maneuvers-a-randomized-crossover-trial
#13
Ariel Berlinski, Dirk von Hollen, Ross H M Hatley, Lucy E A Hardaker, Kurt Nikander
BACKGROUND: Valved holding chambers (VHCs) are used in children to deliver pressurized metered dose inhalers (pMDI). In vitro data suggest that uncoordinated use decreases the amount of drug available for inhalation. We hypothesize that in an ex vivo study, the coordinated maneuver will deliver more drug than the uncoordinated one. PATIENTS AND METHODS: Thirty-two clinically stable asthmatic children, ages 5-8 years, completed the study. An aerosol filter was interposed between a small-volume nonelectrostatic VHC and a mouthpiece to capture the drug emitted by one puff of Flovent(®) 220 mcg during tidal breathing...
December 15, 2016: Journal of Aerosol Medicine and Pulmonary Drug Delivery
https://www.readbyqxmd.com/read/27971531/a-12-week-cost-analysis-to-compare-fluticasone-furoate-vilanterol-and-beclomethasone-dipropionate-formoterol-in-the-treatment-of-mild-to-moderate-asthma
#14
R W Dal Negro, C Distante, L Bonadiman, P Turco, S Iannazzo
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27965772/once-daily-fluticasone-furoate-vilanterol-versus-twice-daily-combination-therapies-in-asthma-mixed-treatment-comparisons-of-clinical-efficacy
#15
Henrik Svedsater, Gillian Stynes, Jaro Wex, Lucy Frith, David Leather, Emanuela Castelnuovo, Michelle Detry, Scott Berry
BACKGROUND: Fluticasone furoate (FF)/vilanterol (VI) is a once-daily inhaled corticosteroid (ICS)/long-acting beta2 agonist (LABA) combination. FF/VI, 92/22mcg and 184/22mcg, are approved in Europe as maintenance therapy in persistent asthma. We report data from mixed treatment comparisons (MTC) of once-daily FF/VI against established twice-daily ICS/LABA combination therapies on clinical efficacy outcomes. METHODS: Data from 31 parallel-group randomised controlled trials (RCTs) of ICS/LABA, of ≥8 weeks' duration in patients aged ≥12 years with asthma, identified by systematic review, were analysed using covariate-adjusted Bayesian hierarchical models for four efficacy outcomes (primary analysis)...
2016: Asthma research and practice
https://www.readbyqxmd.com/read/27959747/salmeterol-and-fluticasone-propionate-in-children-with-asthma
#16
LETTER
Antonio Nieto, Ángel Mazón, María Nieto
No abstract text is available yet for this article.
1, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/27959746/salmeterol-and-fluticasone-propionate-in-children-with-asthma
#17
LETTER
David A Stempel, Stanley J Szefler, Steven J Pascoe
No abstract text is available yet for this article.
1, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/27957745/exploring-new-zealand-prescription-data-using-sequence-symmetry-analyses-for-predicting-adverse-drug-reactions
#18
P S Nishtala, T-Y Chyou
WHAT IS KNOWN AND OBJECTIVE: Prescription sequence symmetry analyses (PSSA) is a ubiquitous tool employed in pharmacoepidemiological research to predict adverse drug reactions (ADRs). Several studies have reported the advantage of PSSA as a method that can be applied to a large prescription database with computational ease. The objective of this study was to validate New Zealand (NZ) prescription database as a potential source for identifying ADRs using the PSSA method. METHODS: We analysed de-identified individual-level prescription data for people aged 65 years and above for the period 2005 to 2014 from the pharmaceutical collections supplied by the NZ Ministry of Health...
December 13, 2016: Journal of Clinical Pharmacy and Therapeutics
https://www.readbyqxmd.com/read/27940272/cost-utility-analysis-of-topical-steroids-compared-to-dietary-elimination-for-treatment-of-eosinophilic-esophagitis
#19
Cary C Cotton, Daniel Erim, Swathi Eluri, Sarah H Palmer, Daniel J Green, W Asher Wolf, Thomas M Runge, Stephanie Wheeler, Nicholas J Shaheen, Evan S Dellon
BACKGROUND & AIMS: Topical corticosteroids or dietary elimination are recommended as first-line therapies for eosinophilic esophagitis (EoE), but data to directly compare these therapies are scant. We performed a cost utility comparison of topical corticosteroids and the 6 food elimination diet (SFED) in treatment of EoE, from the payer perspective. METHODS: We used a modified Markov model based on current clinical guidelines, in which transition between states depended on histologic response simulated at the individual cohort-member level...
December 7, 2016: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/27937064/safety-efficacy-and-dose-response-of-fluticasone-propionate-delivered-via-the-novel-mdpi-in-patients-with-severe-asthma-a-randomized-controlled-dose-ranging-study
#20
David I Bernstein, Michael Gillespie, Sharon Song, Jonathan Steinfeld
OBJECTIVE: Evaluate fluticasone propionate (Fp) using a novel, inhalation-driven, multidose dry powder inhaler (MDPI) in patients with severe persistent asthma, versus placebo MDPI and Fp dry powder inhaler (DPI). METHODS: Patients with persistent asthma despite use of high-dose inhaled corticosteroids were randomized to Fp MDPI 50, 100, 200, or 400 mcg; Fp DPI 250 mcg; or placebo MDPI twice daily for 12 weeks. The primary outcome measure was change from baseline in trough forced expiratory volume in 1 second (FEV1) over the 12-week period, compared with placebo; secondary measures included change from baseline in peak expiratory flow (PEF), rescue inhaler use, and time to withdrawal due to meeting stopping criteria...
October 24, 2016: Journal of Asthma: Official Journal of the Association for the Care of Asthma
keyword
keyword
30179
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"